November 11, 2011
Speaking on “The Divide on Joint Infringement” at the November 3, 2011 BIO IP Counsels Committee Conference in New York, Finnegan partner Kara F. Stoll made the argument that litigation for joint infringement is becoming more and more common in patent cases concerning personalized medicine, especially those that involve the use of web content. Ms. Stoll, who represents the appellant in Akamai Technologies Inc. v. Limelight Networks Inc., discussed her case involving different actors performing different steps in method patent claims. For example, in the Akamai matter, the patent in question covers an improved method of delivering web page content in which the content provider, such as a website, delivers part of the page and the content delivery network, delivers the remainder of the content.
Award/Ranking
Finnegan Named Firm of the Year at the 2024 Managing Intellectual Property Americas Awards
April 26, 2024
Commentary
World IP Day: EPO Reveals 33% Jump in Cleantech Inventions Over Five Years
April 26, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.